OliX Pharmaceuticals, Inc (226950.KQ)

15,200.00 +490.00 (+3.33%) At close: 03:30PM KST

OliX Pharmaceuticals, Inc

Ace Gwanggyo Tower1
Suite 1014 17, Daehak 4-ro, Yeongtong-gu
Suwon-si 16226
South Korea
82 3 1779 8400
https://www.olixpharma.com

Sector(s): 
Industry: 
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dong-Ki Lee Ph.D.	CEO & Director	N/A	N/A	1972
Jin Kim Young	Director of Finance Dept.	N/A	N/A	N/A
Ms. Young Hye Baek	Executive Director of Legal Affairs	N/A	N/A	N/A
Ms. Shin Young Park Ph.D.	Executive Vice President of Development Dept.	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

Corporate Governance

OliX Pharmaceuticals, Inc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.